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Abstract 
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Abstract 
 
Most of the commonly used antidepressants block monoamine reuptake 
transporters to enhance serotonergic or noradrenergic neurotransmission. 
Effects besides or downstream of increased monoaminergic 
neurotransmission are poorly understood and yet presumably important for 
the drugs’ mode of action. In my PhD thesis I employed proteomics and 
metabolomics technologies combined with in silico analyses and identified 
cellular pathways affected by antidepressant drug treatment. DBA/2 mice 
were treated with paroxetine as a representative Selective Serotonin 
Reuptake Inhibitor (SSRI). Hippocampal protein levels were compared 
between chronic paroxetine- and vehicle-treated animals using in vivo 15N 
metabolic labeling combined with mass spectrometry. I also studied chronic 
changes in the hippocampus using unbiased metabolite profiling and the time 
course of metabolic changes with the help of a targeted polar metabolomics 
profiling platform. I identified profound alterations related to hippocampal 
energy metabolism. Glycolytic metabolite levels acutely increased while Krebs 
cycle metabolite levels decreased upon chronic treatment. Changes in energy 
metabolism were influenced by altered glycogen metabolism rather than by 
altered glycolytic or Krebs cycle enzyme levels. Increased energy levels were 
reflected by an increased ATP/ADP ratio and by increased ratios of high-to-
low energy purines and pyrimidines. Paralleling the shift towards aerobic 
glycolysis upon paroxetine treatment I identified decreased levels of Krebs 
cycle and oxidative phosphorylation enzyme levels upon the antidepressant-
like 15N isotope effect in high-anxiety behavior mice. In the course of my 
analyses I also identified GABA, galactose-6-phosphate and leucine as 
biomarker candidates for the assessment of chronic paroxetine treatment 
effects in the periphery and myo-inositol as biomarker candidate for an early 
assessment of chronic treatment effects. The identified antidepressant drug 
treatment affected molecular pathways and novel SSRI modes of action 
warrant consideration in antidepressant drug development efforts. 
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1 INTRODUCTION 
 
1.1 Major depressive disorder and the monoamine deficiency 
hypothesis of depression 
 
1.1.1 Major depressive disorder 
 
Major depressive disorder (MDD) is a severe and life-threatening disease 
(about 15% of depressed patients commit suicide (Manji et al., 2001)) with a 
population prevalence of 17% (Kessler et al., 2007; Burmeister et al., 2008). 
By the year 2030 major depression is projected to be the second leading 
contributor to the global burden of disease (disability adjusted life years, 
DALY) and the leading contributor in high-income countries (Mathers and 
Loncar, 2006).  
MDD etiology is poorly understood and there are no objective diagnostic tests 
available. The diagnosis of depression is based on a highly subjective and 
variable set of symptoms such as depressed mood, loss of interest, 
diminished sense of pleasure, irritability, low self-esteem, weight loss or 
weight gain, insomnia or hypersomnia or recurrent thoughts of death and 
suicide that last for more than two weeks and disrupt normal social and 
occupational functioning (Nestler et al., 2002; Mann, 2005). 
 
1.1.2 Current antidepressant treatment and the monoamine deficiency 
hypothesis of depression 
 
More than 50 years ago it was observed serendipitously that the monoamine 
oxidase inhibitor (MAOI) iproniazid, initially developed for the treatment of 
tuberculosis (Bloch et al., 1954), and the tricyclic agent (TCA) imipramine, 
initially developed for the treatment of psychotic disorders (Kuhn, 1958), 
exerted antidepressant effects in man. Iproniazid increased monoamine levels 
by inhibiting their catabolism by monoamine oxidase and imipramine amplified 
monoamine signaling by inhibiting monoamine reuptake at the presynapse.  
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Based on these findings the monoamine deficiency hypothesis of depression 
proposed that increasing synaptic availability of monoamines elicits 
antidepressant effects and that MDD involved the decrease of monoamines in 
the brain (Schildkraut, 1965; Coppen, 1967; Wong and Licinio, 2004). 
In the 1980s, based on the monoamine deficiency hypothesis of depression, 
antidepressant drug development efforts focused on the rational design of 
agents with selective monoamine-uptake inhibitory properties. Selective 
Serotonin Reuptake Inhibitors (SSRIs, e.g. paroxetine, fluoxetine) (Vaswani et 
al., 2003, see Figure 1) and, to a lesser extent, Selective Noradrenaline 
Reuptake Inhibitors (SNRIs, e.g. reboxetine) (Brunello et al., 2003) were 
developed that did not affect other neuroreceptor systems for increased safety 
and tolerability. According to meta-analyses, SSRIs and SNRIs exhibit 
favorable side effect profiles but equal treatment efficacy and onset of action 
compared to TCA treatment (Song et al., 1993; Montgomery et al., 1994; 
Anderson, 2000; Peretti et al., 2000). Shortcomings of current monoaminergic 
antidepressant treatment include a delayed onset of therapeutic action (up to 
2-8 weeks), adverse side effects (e.g. sexual dysfunction or sleep 
disturbances) and a low response rate (about 50-80%) (Holsboer, 2001; 
Wong and Licinio, 2004; Berton and Nestler, 2006). 
To face the challenges of increasing numbers of depressive patients and 
increasing economic burden in the coming decades it is mandatory to have 
better antidepressant drugs at hand with increased efficacy, less side effects 
and faster onset of therapeutic action. 
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Figure 1. Mode of SSRI drug action.  
Selective serotonin reuptake inhibitors 
increase serotonergic neurotransmission 
by blocking serotonin transporters in the 
presynapse.  
Reproduced with permission from 
(Mann, 2005), Copyright Massachusetts 
Medical Society. 
 
 
 
 
 
1.2 Antidepressant treatment effects beyond monoamine 
reuptake inhibition 
 
Contrary to the monoamine deficiency hypothesis of depression, monoamine 
depletion does not induce depression in healthy humans (Ruhe et al., 2007). 
Moreover, although pharmacological modulation of monoamine receptors 
represents an acute antidepressant treatment effect therapeutic effects are 
delayed by several weeks (Gould and Manji, 2002). Additionally, a study by 
Nickel et al. (Nickel et al., 2003) found that serotonin reuptake inhibition (by 
paroxetine treatment) and serotonin reuptake enhancement (by tianeptine 
treatment) elicit antidepressant effects. Both paroxetine and tianeptine 
treatment normalized hypothalamic-pituitary-adrenal (HPA) axis reactivity, 
indicating that opposite effects on the serotonin system may lead to common 
downstream pathway alterations. 
The most parsimonious explanation for these findings is that monoamine 
elevation per se is not the only source for therapeutic antidepressant activity 
but secondary long-term downstream effects may also be involved in the 
alleviation of depressive symptoms (Brady et al., 1992; Michelson et al., 1997; 
Holsboer, 2001). It is tempting to speculate that for improved antidepressant 
treatment it would be beneficial to pharmacologically interfere with these 
downstream mechanisms directly.  
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The following chapters (1.2.1-1.2.4) overview the major hypotheses of 
antidepressant treatment effects beyond monoamine reuptake inhibition. It is 
important to note that this overview is not exclusive, there is no consensus on 
which effects are most relevant for therapeutic action and molecular 
antidepressant treatment effects in general remain elusive. 
 
1.2.1 Intracellular signaling events upon antidepressant treatment 
 
Monoaminergic neurotransmission is mainly mediated via G-protein coupled 
receptor (GPCR) signaling and different monoamine receptor families are 
coupled to different G-proteins. Dependent on the receptor subtype two major 
´prototypical´ intracellular signal transduction pathways are involved: (1) 
cAMP signaling upon Gi/o or Gs activation and (2) phosphatidylinositol 
signaling upon Gq activation. Gi/o inhibits adenylate cyclase (AC) activity 
leading to reduced second messenger cAMP generation and in turn reduced 
protein kinase A (PKA) activity whereas Gs activates AC activity leading to 
increased PKA activity. Gq activates phospholipase C (PLC) leading to 
increased generation of the second messengers inositol phosphate (IP) and 
diacylglycerol (DAG) and in turn increased protein kinase C (PKC) activity. 
PKA and PKC mediated protein phosphorylation eventually lead to gene 
expression alterations (Millan et al., 2008). PKA phosphorylates the cAMP 
response element binding protein (CREB) that in turn binds to the cAMP 
response element (CRE), a gene element found in the promoters of a few 
thousand genes (Gould and Manji, 2002; Impey et al., 2004). 
Despite extensive cross-talk between PKA and PKC mediated systems, 
antidepressant treatment is believed to mainly influence cAMP/PKA signaling 
cascades and phosphatidylinositol/PKC signaling seems less relevant 
(Shelton, 2000; Perera et al., 2001). Specifically, chronic antidepressant 
treatment alters mRNA and protein levels of G protein alpha subunits in a 
brain region- and antidepressant drug-specific manner (Lesch and Manji, 
1992; Li et al., 1996; Li et al., 1997; Raap et al., 1999). Antidepressant 
treatment also induces a translocation of PKA from the cytosol to the nucleus 
in rat frontal cortex cells (Nestler et al., 1989) and increases PKA dependent 
phosphorylation events (Perez et al., 1989; Perez et al., 1991).  
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1.2.2 Induced neurogenesis upon antidepressant treatment 
 
Long-term antidepressant treatment increases cellular CREB mRNA, CREB 
protein and CREB/CRE binding in the hippocampus (Nibuya et al., 1995; 
Nibuya et al., 1996; Duman et al., 1997). The same studies found that the 
CREB regulated gene products BDNF and its receptor trkB were upregulated 
upon long-term treatment. Other studies indicate that antidepressant 
treatment regulates CREB in a brain region-specific manner and that CREB 
exerts opposing effects on depression-like features in different brain regions 
(Schwaninger et al., 1995; Nibuya et al., 1996; Manier et al., 2002; Newton et 
al., 2002).  
CREB and the neurotrophin BDNF have been considered key regulators of 
neuronal survival and plasticity, including neurogenesis and synaptogenesis 
(Nakagawa et al., 2002; Castren, 2004; Malberg and Blendy, 2005; Gass and 
Riva, 2007). Antidepressant treatment appears to protect against hippocampal 
volume loss in depressed patients (Sheline et al., 2003), antidepressant drugs 
enhance neurogenesis in rodent hippocampi (Malberg et al., 2000) and 
Santarelli et.al. (Santarelli et al., 2003) have shown that hippocampal 
neurogenesis is required for antidepressant induced behavioral effects in 
mice. Based on these findings the neurotrophic hypothesis of depression 
postulates that hippocampal neuronal atrophy (due to stress and decreased 
expression of BDNF and other growth factors) contributes to depression and 
antidepressant treatment effects derive from an upregulation of BDNF in the 
hippocampus (Wong and Licinio, 2004; Duman and Monteggia, 2006).  
 
1.2.3 Altered stress response upon antidepressant treatment 
 
Hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis is a putative 
risk factor predisposing to the development of depression. A significant 
percentage of depressed patients exhibit HPA axis hyperactivity due to, at 
least in part, impairment of corticosteroid receptor function which is also 
reflected by an inappropriate response in the dexamethasone/corticotropin-
releasing hormone (DEX/CRH) test (Holsboer, 2001; Pariante and Lightman, 
2008). Successful antidepressant treatment is associated with resolution of 
1 INTRODUCTION 
6 
 
the impairment in the negative feedback on the HPA axis by glucocorticoids 
(Pariante, 2006). 
The CRH promotor region contains a CRE sequence (Spengler et al., 1992) 
and antidepressants may influence the stress system via PKA mediated 
signaling and regulation of CREB. Indeed, antidepressant treatment reduces 
CRH concentrations in the cerebrospinal fluid (CSF) (Nemeroff et al., 1991; 
De Bellis et al., 1993; Veith et al., 1993; Heuser et al., 1998). Additionally, 
antidepressant treatment decreases HPA axis stress reactivity associated with 
increased binding capacity of corticosteroid receptors in the hippocampus 
(Reul et al., 1994), alters glucocorticoid receptor (GR) expression, and 
improves GR function and GR-mediated feedback inhibition (Brady et al., 
1991; Brady et al., 1992; Michelson et al., 1997; Holsboer, 2001; Pariante and 
Lightman, 2008). 
1.2.4 Unifying link between distinct mechanisms of antidepressant drug 
action 
 
A recent study identified a putative link between antidepressant treatment 
induced changes on intracellular PKA mediated signaling (see chapter 1.2.1), 
neurogenesis (see chapter 1.2.2) and the HPA axis (see chapter 1.2.3). 
Specifically, in vitro experiments indicated that induced neurogenesis upon 
SSRI (sertraline) treatment is dependent on GR function that is associated 
with GR phosphorylation via PKA activity (Anacker et al., 2011). This and 
other findings indicate that distinct hypotheses for the mode of antidepressant 
action do not compete and exclude each other but rather complement each 
other (Perera et al., 2001).  
Taken together, despite tremendous efforts during the last decades, the 
precise mechanism of antidepressant action remains elusive and studies on 
current antidepressant treatment effects are in great demand for a better 
understanding of antidepressant elicited therapeutic as well as side effects.   
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1.3 Biomarker discovery 
 
1.3.1 Biomarkers and surrogate endpoints 
 
Biomarkers are used as diagnostic tools for the objective determination of 
disease state, disease progression, disease prognosis or treatment effects 
and response. According to the National Institutes of Health, a biomarker is “a 
characteristic that is objectively measured and evaluated as an indicator of 
normal biological processes, pathogenic processes, or pharmacological 
responses to a therapeutic intervention” (Biomarkers Definitions Working 
Group, 2001). A biomarker that is reasonably likely to predict clinical benefit 
may also be used as surrogate endpoint, i.e. be used as “biomarker that is 
intended to substitute for a clinical endpoint. A surrogate endpoint is expected 
to predict clinical benefit (or harm or lack of benefit or harm) based on 
epidemiologic, therapeutic, pathophysiologic, or other scientific evidence” 
(Biomarkers Definitions Working Group, 2001). 
 
1.3.2 Biomarkers for antidepressant treatment effects 
 
At present there are no biomarkers that are used in clinical practice for any 
psychiatric disorder. Biomarkers for antidepressant treatment response could 
accelerate drug discovery as surrogate endpoints and hence reduce 
production costs and pipeline development time (Schwarz and Bahn, 2008). 
Biomarkers could help to predict antidepressant treatment response early in 
the course of treatment in order to minimize protracted serial trial-and-error 
(Rush et al., 2009; Leuchter et al., 2010), inform on drug dosing and help 
minimize inter-individual variation in antidepressant treatment response  
(Biomarkers Definitions Working Group, 2001). 
Because psychiatric diseases are considered complex disorders of the brain, 
major affected biochemical pathways in disease or upon treatment are 
expected to be primarily altered in the brain. Plasma, on the other hand, is the 
preferred specimen for a biomarker assay due to its accessibility, reproducible 
sampling methods and the fact that small brain molecules are excreted via 
plasma (Leuchter et al., 2010). The ideal biomarker for psychiatric disorders 
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would be measured in the periphery and represent a highly sensitive and 
specific indicator of disease pathways in the brain. 
Due to the complex etiology and polygenic character of psychiatric disorders 
biomarker signatures rather than single biomarkers are expected to depict 
more accurately behavioral phenotype changes (Filiou et al., 2011a). A single 
biomarker will usually have small effect sizes and several biomarkers need to 
be combined for a robust prediction of disease state or treatment effects 
(Singh and Rose, 2009).  
 
1.4 Mouse models in antidepressant treatment research 
 
Although human material is the most relevant specimen for the analysis of 
psychiatric disease etiology and antidepressant treatment effects, exploratory 
studies frequently rely on the investigation of rodent brains (Nakatani et al., 
2004; Wong and Licinio, 2004; Yamada and Higuchi, 2005; Conti et al., 2007; 
Sillaber et al., 2008) for the following reasons: (1) fresh human brain tissue, 
the most relevant organ for psychiatric disorders, is inaccessible due to ethical 
reasons (Sullivan et al., 2006); (2) human post mortem brain, cerebrospinal 
fluid (CSF) or plasma are of limited availability; (3) the inter-individual genetic 
and life style variability combined with the low sample quantity available pose 
serious challenges for analytical efforts (Filiou and Turck, 2011); (4) the 
presence of confounding factors like brain pH, post mortem interval, age, use 
of antidepressant or other drugs, smoking or substance abuse complicate 
statistical data analyses and thus (5) a great number of biological replicates is 
needed (Kim and Webster, 2009).  
Therefore, for the exploratory phase of the antidepressant-affected pathways 
or biomarker signature discovery pipeline, animal model based studies tend to 
have higher success rates (Turck et al., 2005; Filiou and Turck, 2011). Animal 
models in combination with proteomic and metabolomic technologies promise 
to be useful tools for the hypothesis-free discovery of biomarker candidates 
(Turck et al., 2005; Reckow et al., 2008; Filiou and Turck, 2011). 
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1.4.1 Mouse models for psychiatric disorders 
 
Major depression involves complex thought processes and emotions and it is 
not possible to model depression in mice in its entirety (Wong and Licinio, 
2004). However, mouse models were successfully developed that model 
certain features, i.e. endophenotypes, of the disease by resembling selected 
characteristics of the human condition. Current animal models for depression-
like behavior include uncontrollable stress models (e.g. forced swim test 
(FST), tail suspension test (TST)), reward models (e.g. sucrose prevalence), 
olfactory bulbectomy, chronic mild stress, drug withdrawal, maternal 
deprivation, neonatal clomipramine and genetic models (reviewed in (Wong 
and Licinio, 2004)). Important criteria for mouse models of depression are (1) 
face validity, i.e. whether the model phenomenologically resembles the human 
condition; (2) predictive validity, i.e. whether the performance of the model in a 
test is predictive for human performance and (3) construct/etiological validity, 
i.e. how accurately the test models the human condition and whether the 
model is based on known etiological factors. Predictive validity is sometimes 
used to indicate pharmacological isomorphism, i.e. whether the model 
predicts antidepressant treatment response in humans (Van Dam and De 
Deyn, 2006; Markou et al., 2009).  
There are various models available to investigate the effects of currently used 
and novel antidepressants in mice. The following chapter (1.4.2) will focus on 
an animal model that was utilized in the present thesis for (1) the 
characterization of antidepressant treatment affected molecular pathways and 
(2) for the identification of biomarker candidates for antidepressant treatment 
effects. The subsequent chapter (1.4.3) will focus on an animal model of 
anxiety-related behavior and the recently discovered antidepressant-like 15N 
isotope effect that was utilized for correlating antidepressant-like effects with 
molecular pathway alterations.   
 
1.4.2 Paroxetine treatment of DBA/2 mice  
 
Paroxetine is the most potent inhibitor of serotonin reuptake (Sanchez and 
Hyttel, 1999; Bourin et al., 2001) and a weak inhibitor of norepinephrine 
reuptake (Kelly and Leonnard, 1995; Sugimoto et al., 2011). The ratio of 
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inhibition of uptake of norepinephrine to serotonin (NE/5-HT) is second only to 
that of citalopram. There is a negligible affinity for other receptor systems, 
including catecholaminergic, dopaminergic, histaminergic and muscarinic 
cholinergic systems (Bourin et al., 2001). Next to depression the SSRI 
paroxetine is also used for treating panic disorder, obsessive compulsive 
disorder and social phobia (Wagstaff et al., 2002). 
The inbred DBA/2 mouse strain displays a high level of innate anxiety-like 
behavior (Ohl et al., 2003) that is potentially linked to distinct neurotransmitter 
receptor densities (Yilmazer-Hanke et al., 2003), may exhibit aspects of 
hippocampal dysfunction (Thinus-Blanc et al., 1996) and displays a reduced 
HPA axis feedback inhibition compared to other inbred mouse strains 
(Thoeringer et al., 2007). DBA/2 mice are more sensitive towards paroxetine 
treatment compared to other mouse strains, as determined in the FST 
(Sugimoto et al., 2011). These studies suggest that DBA/2 mice reflect some 
psychiatric disorders endophenotypes and therefore might be suitable for the 
investigation of molecular antidepressant treatment effects (Sillaber et al., 
2008). Paroxetine treatment of DBA/2 mice results in decreased passive 
stress coping behavior in the FST, an indication of antidepressant treatment 
efficacy in rodents (Porsolt et al., 1977).  
Sillaber et al. investigated paroxetine induced alterations in DBA/2 mice at the 
mRNA level using transcriptomic analyses (Sillaber et al., 2008). In the 
present thesis the focus was expanded to the identification of molecular 
pathway alterations using proteomic and metabolomic analyses and the 
identification of biomarker candidates for antidepressant treatment effects. 
 
1.4.3 The HAB/LAB mouse model and the antidepressant-like 15N isotope 
effect in anxious HAB mice 
 
The high anxiety-related behavior (HAB)/low anxiety-related behavior (LAB) 
mouse model is based on selective bidirectional breeding of mice for 
behavioral extremes according to their performance on the elevated plus-
maze (EPM), a behavioral paradigm assessing anxiety-related behavior. HAB 
mice spend most of their time in the closed arms whereas LAB mice spend 
most of their time in the open arms (Pellow et al., 1985; Kromer et al., 2005). 
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Selective bidirectional inbreeding led to the enrichment of the genetic material 
associated with the anxiety phenotype (Landgraf et al., 2007; Plomin et al., 
2009). The high comorbidity of anxiety with depression is reflected in HAB 
mice by an increased passive stress coping behavior in the FST and TST 
compared to LAB mice (Kromer et al., 2005; Landgraf et al., 2007). 
In previous efforts for relative protein quantification 15N metabolic labeling was 
applied to the HAB/LAB mouse model for the comparison of HAB and LAB 
proteomes (Filiou et al., 2011b; Zhang et al., 2011b). For that purpose mice 
were fed a diet enriched with the stable, heavy 15N isotope (>97% 15N) 
resulting in an enrichment of the 15N isotope in the organism. Intriguingly, the 
introduction of the stable 15N isotope resembled antidepressant treatment 
effects on the behavioral phenotype of HAB mice in the TST. We therefore 
carried out unbiased proteomic analyses of this antidepressant-like 15N 
isotope effect in order to discover pathways that are potentially involved in 
antidepressant-like actions in the HAB mouse model (Frank et al., 2009).   
 
 
1.5 Mass spectrometry based quantitative proteomics and 
metabolomics 
 
1.5.1 Genomics and functional genomics in psychiatry research 
 
Major depression is a complex, hereditary and polygenetic disease. The 
interplay of the genetic setup with environmental factors is believed to play a 
crucial role in psychiatric disease development (Taurines et al., 2011). There 
is a great demand for integrative analyses across a wide range of fields 
including omics-based systems biology strategies for a better understanding 
of disease related pathways (Kitano, 2002; Barabasi and Oltvai, 2004). 
After the complete sequencing of the human genome about 10 years ago 
(Lander et al., 2001; Venter et al., 2001), psychiatry research has applied 
genomic approaches in human studies leading to valuable, though 
unfortunately limited, insights into disease pathways, treatment response and 
novel drug targets (Lucae et al., 2006; Burmeister et al., 2008; Sillaber et al., 
2008; McQuillin et al., 2009). 
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Functional genomics (i.e. post-genomics) including transcriptomics, 
proteomics and metabolomics adds a very important new dimension to the 
study of psychiatric disorders: the analysis of spatial and temporal system 
alterations. Consequently, functional genomics facilitates an accurate and 
unbiased generation of hypotheses for pathophysiology and drug action 
mechanisms (Turck et al., 2005; Geschwind and Konopka, 2009).  
Both transcriptomics and proteomics were successfully applied to the 
elucidation of antidepressant treatment affected pathways in rodents 
(Khawaja et al., 2004; Carboni et al., 2006; Cecconi et al., 2007; McHugh et 
al., 2008; Sillaber et al., 2008; McHugh et al., 2010). Compared to 
transcriptomics, proteomics exhibits several advantageous characteristics: (1) 
the level of mRNA does not always reflect protein expression indicating the 
need for complementary proteomics analyses; (2) proteomics allows for 
organelle specific analyses facilitating e.g. synapse specific alterations; (3) 
protein post-translational modifications (PTM) play an important role in protein 
function and activity, but this aspect is undetectable by transcriptomics and (4) 
proteins are the actual contributors to biochemical pathway activities and 
biological processes and therefore are more closely related to disease 
phenotype. 
With the advance of novel instrumentation and data analysis strategies 
metabolomics represents the latest of functional genomics technology. 
Metabolomics complements transcriptomics and proteomics investigations 
especially in the area of systems biology and pathway analysis because 
metabolites are the final products of interactions between gene expression, 
protein expression and the cellular environment (Kaddurah-Daouk and 
Krishnan, 2009). At present only a limited number of studies have been 
performed investigating effects of antidepressant treatment at the metabolome 
level (Paige et al., 2007; Dai et al., 2010; Ji et al., 2011; Su et al., 2011).  
The following chapters describe quantitative proteomic (1.5.2) and 
metabolomic (1.5.3) technologies with a focus on methods that were used in 
the current thesis.  
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1.5.2 Quantitative proteomics 
 
Traditional proteomics strategies predominately exploited two-dimensional gel 
electrophoresis for high resolution protein separation and relative protein 
quantification. Complex protein mixtures (e.g. derived from brain tissue) are 
first separated according to their isoelectric point and in a second dimension 
by molecular weight. Staining of the proteins allows the identification of both 
quantitative (expression level) and qualitative (mainly post-translational 
modification) protein differences. Differentially expressed proteins between 
disease/treatment vs. control are then identified using mass spectrometry 
(O'Farrell, 1975). Limitations of two-dimensional gel electrophoresis include 
low throughput, limited dynamic range, low sensitivity, high technical variability 
and incompatibility for hydrophobic membrane proteins (Fey and Larsen, 
2001; Lubec et al., 2003). Therefore quantitative proteomics has recently 
shifted towards shotgun proteomics approaches that aim at identifying and 
quantifying as many proteins as possible in a given sample by utilizing highly 
sensitive mass spectrometry (MS) in combination with multidimensional 
protein and peptide separation techniques.  
 
1.5.2.1 The impact of tandem mass spectrometry in modern proteomics 
 
Mass spectrometry is an analytical approach that measures the mass-to-
charge (m/z) ratio of ions. In a typical bottom-up proteomics experiment MS is 
used to analyze peptides in complex protein digests (Steen and Mann, 2004). 
Peptide information is then conferred to corresponding proteins. For increased 
sensitivity sample complexity has to be reduced prior to mass spectrometry 
analysis at the protein level (e.g. by SDS gel electrophoresis or isoelectric 
focusing) and/or at the peptide level (e.g. by strong cation exchange or 
reversed phase high performance liquid chromatography). 
The main components of a mass spectrometer are an ionization source, a 
mass analyzer and an ion detector. Current MS-based proteomics became 
possible only after the introduction of soft ionization methods like matrix-
assisted-laser-desorption ionization (MALDI) (Karas and Hillenkamp, 1988), 
electrospray ionization (ESI) (Whitehouse et al., 1985) and, for increased 
sensitivity, nanospray ionization (NSI) (Shevchenko et al., 1996b; Shevchenko 
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et al., 1996a; Wilm and Mann, 1996; Wilm et al., 1996). There are different 
kinds of mass analyzers that, depending on the analytical question, exhibit 
distinct strengths and advantages. Mass analyzers include quadrupole (Q) 
mass filter, linear ion trap (LTQ), Orbitrap, time-of-flight (TOF), magnetic 
sector, ion cyclotron resonance (ICR), and combinations thereof like Triple-
Quadrupole (QqQ), Q-TOF or LTQ-Orbitrap instruments.  
LTQ-Orbitrap hybrid mass spectrometers are the instruments of choice for 
shotgun proteomics due to the high sensitivity, high scan rate, high dynamic 
range (>103), high mass accuracy (<5 ppm) and high mass resolution (up to 
100.000 at m/z 400) (Yates et al., 2006). The final readout of all mass 
spectrometers is a mass spectrum (MS spectrum) which is a recording of the 
signal intensity of the ion at each value of the m/z scale (Steen and Mann, 
2004).   
Tandem mass spectrometry involves the fragmentation of precursor ions and 
m/z determination of product ions resulting in the generation of MS/MS 
spectra. By in silico comparison of precursor ion and fragment ion masses 
with a protein database it is then possible to identify peptides and 
corresponding proteins (Eng et al., 1994; Perkins et al., 1999). Fragmentation 
methods include collision-induced dissociation (CID), higher energy collision 
dissociation (HCD), or electron transfer dissociation (ETD).  
 
1.5.2.2 Quantitative proteomics using stable isotope labeling 
 
Mass spectrometry signal intensities are not a measure of protein amount 
because different peptides have different physico-chemical properties like 
solubility or ionization efficiency. However, because these factors are 
reproducible relative quantification is possible by using label free quantitation 
strategies (Bondarenko et al., 2002; Chelius and Bondarenko, 2002; Higgs et 
al., 2008) or strategies based on stable isotope labeling (Gygi and Aebersold, 
2000; Steen and Mann, 2004).  
According to the isotope dilution theory (De Leenheer, 1992), peptides that 
differ only in isotopic composition behave identically during an LC-MS 
experiment. Therefore, the ratio of unlabeled and labeled peptides within a 
mass spectrum or the ratio of extracted ion chromatograms represents an 
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accurate measure of relative protein concentration (Steen and Mann, 2004). 
Stable isotopes that are used for labeling of proteins or peptides include 2H, 
13C, 15N and 18O, leading to a great variety of different methods for relative 
protein quantification like ICAT (Gygi et al., 1999), ICPL (Schmidt, 2005), 
iTRAQ (Ross et al., 2004), 18O labeling (Reynolds et al., 2002), SILAC (Ong 
et al., 2002) and 15N metabolic labeling (Oda et al., 1999). Unlabeled and 
labeled samples are combined at different experimental stages leading to 
different quantitation accuracies. If unlabeled and labeled samples are 
combined at the very beginning of sample preparation, as is the case for 
SILAC or 15N metabolic labeling, quantitation accuracy is maximal because 
potential experimental biases affect both labeled and unlabeled sample in the 
same way and the ratio remains unchanged (Bantscheff et al., 2007; 
Bantscheff et al., 2012)(Figure 2). Therefore, SILAC and 15N metabolic 
labeling represent the current gold standard for accurate relative protein 
quantification. 15N metabolic labeling has been used in several model 
organisms including yeast (Oda et al., 1999), bacteria(Pan et al., 2008), 
Drosophila melanogaster (Krijgsveld et al., 2003), Caenorhabditis elegans 
(Dong et al., 2007), plants (Huttlin et al., 2007), mice (Huttlin et al., 2009; 
Filiou et al., 2011b; Zhang et al., 2011b) and rats (Wu et al., 2004). To avoid 
any biases due to the labeling itself the labeled sample is frequently used as 
internal standard for indirect comparison of relative protein levels (Pan et al., 
2008). 
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Figure 2. Quantitative proteomics workflows. If samples are combined 
prior to sample preparation, as seen in metabolic labeling approaches, 
quantitation accuracy is optimal. Blue and orange boxes represent two 
experimental conditions, horizontal lines indicate when samples are combined 
and dashed lines indicate possibilities for experimental variation. Reproduced 
with permission from (Bantscheff et al., 2007).  
 
1.5.3 Quantitative metabolomics 
 
Quantitative metabolomics complements previous -omics efforts due to its 
integrative capacity and was recently introduced into psychiatric research 
(Kaddurah-Daouk et al., 2007; Paige et al., 2007; Dai et al., 2010; Ji et al., 
2011; Su et al., 2011).  
A major challenge in metabolomic analyses is the large dynamic range (>106) 
and great chemical diversity of metabolites like amino acids, amino sugars, 
oligosaccharides, fatty acids or lipids. Another drawback is the absence of 
reliable and automated metabolite identification tools (Moco et al., 2007).  
Due to the chemical variety diverse complementary analytical methods 
including sample preparation need to be applied for a comprehensive and 
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hypothesis-free holistic analysis. Depending on the biological question, 
however, the analysis of sub-metabolomes or targeted analyses may reveal 
significant insights into the system of interest. Most commonly used platforms 
are based on LC-MS (liquid chromatography-MS), GC-MS (gas 
chromatography-MS) and NMR (nuclear magnetic resonance) (Moco et al., 
2007; Theodoridis et al., 2012). 
Acquisition of NMR spectra of complex mixtures like biofluids, so called NMR 
fingerprinting, is used for the identification of biomarker patterns. NMR is a 
quantitative technique well suited for metabolomics analyses but lacks 
sensitivity compared to MS-based methods.  
GC-MS was applied to metabolomics studies much earlier than LC-MS and 
offers high sensitivity, high resolution power, high throughput, excellent 
reproducibility, and highly reproducible fragmentation patterns. Disadvantages 
include tedious sample preparation because samples need to be derivatized 
before analysis and only volatile (or volatile-made) metabolites with molecular 
weights below 400-500Da can be analyzed (Tolstikov, 2009; Theodoridis et 
al., 2012). 
LC-MS is the most widely used technique in metabolomics. Metabolites are 
first  separated using reversed phase (RP) chromatography for hydrophobic 
compounds (e.g. phenolic acids, flavonoids) and hydrophilic chromatography 
(HILIC) for hydrophilic and neutral compounds (e.g. sugars, amino acids, 
nucleotides) (Tolstikov and Fiehn, 2002). Metabolite ions are generated by 
electrospray ionization (ESI, in positive or negative mode) or atmospheric 
pressure ionization (API). Ions are then analyzed mainly using quadrupole-
time-of-flight (Q-TOF) instruments because of their high sensitivity, mass 
resolution (about 10.000) and mass accuracy with limitations in dynamic 
range. Metabolite ions may also be analyzed using FT-Orbitrap or FT-ICR-MS 
instruments for highest mass resolution (100.000-1.000.000) and mass 
accuracy (<2ppm) facilitating metabolite identification. Metabolites are 
identified using characteristic parameters like metabolite mass, isotopic 
distribution, fragmentation pattern and retention time (Moco et al., 2007).  
Metabolomics analyses may also be performed in a targeted fashion. 
Targeted analyses mainly exploit Multiple-Reaction-Monitoring (MRM) on 
Triple-Quadrupole mass spectrometers that allow for accurate and 
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unambiguous quantification of metabolite precursor and product ions (Lu et 
al., 2008). Recently, a metabolomics platform was introduced targeting 
metabolites involved in cellular metabolism using LC-MRM-MS. The platform 
reliably quantifies more than 250 metabolites involved in major metabolic 
pathways, including glycolysis, Krebs cycle and metabolism of amino acids 
(Kelly et al., 2011; Yuan et al., 2012).  
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1.6 Aim and scope of thesis 
The aim of the current thesis was to define antidepressant treatment effects at 
the molecular pathway level in mouse models using state of the art proteomic 
and metabolomic technologies. A further aim was to identify biomarker 
candidates for antidepressant treatment effects. 
 
Specific aims of the individual manuscripts: 
 
Chapter 2.1: Metabolite profiling of antidepressant drug action reveals novel 
drug targets beyond monoamine elevation 
- Identification of paroxetine treatment affected molecular pathways 
beyond serotonin reuptake inhibition in hippocampus of chronically 
treated DBA/2 mice at the metabolome level. 
- Identification of potential drug targets that may modulate these 
pathways. 
- Identification of metabolite biomarker candidates in plasma. 
 
Chapter 2.2: Proteomic and metabolomic profiling reveals time-dependent 
changes in hippocampal metabolism upon paroxetine treatment and 
biomarker candidates 
- Identification of paroxetine treatment affected molecular pathways 
beyond serotonin reuptake inhibition in hippocampus at the 
metabolome and proteome levels.  
- Identification of time course alterations. 
- Identification of metabolite biomarker candidates in plasma.     
 
Chapter 2.3: The 15N isotope effect as a means for correlating phenotypic 
alterations and affected pathways in a trait anxiety mouse model 
- Identification of molecular correlates of the behavioral antidepressant-
like 15N isotope effect in various brain regions at the proteome level. 
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3 DISCUSSION AND FUTURE PERSPECTIVES 
 
The implementation of functional genomics in psychiatry research - in 
particular high throughput proteomics and metabolomics - is only at its very 
beginning and its great potential is just being realized. In a disease with 
unknown etiology like major depression exploratory and unbiased -omics 
studies in well-established mouse models are of major importance to generate 
novel hypotheses of disease etiology and mode of drug action. Before 
reaching clinical significance, generated hypotheses have to be further 
addressed, validated or modified in targeted studies in other mouse models 
and clinical settings.  
In the present study we employed proteomics and metabolomics technologies 
in combination with in silico pathway analyses in order to define 
antidepressant treatment effects in mouse models. DBA/2 mice were treated 
with paroxetine and molecular pathway alterations identified upon treatment 
with a representative SSRI. The antidepressant-like 15N isotope effect on the 
HAB proteome was investigated and antidepressant-like behavioral and 
molecular alterations correlated. In addition, metabolite biomarker candidates 
for paroxetine treatment effects that reflect hippocampal alterations were 
identified in plasma.  
Most importantly, we have shown that antidepressant treatment affects a 
great variety of biochemical pathways and is not restricted to alterations in 
monoaminergic neurotransmission. Novel hypotheses for the mode of 
antidepressant drug action were generated that lay the ground for future 
investigations in the quest for improved antidepressant treatment strategies. 
 
3.1 Antidepressant treatment influences key cellular 
processes 
 
Psychiatric disorders have traditionally been viewed as neurochemical 
diseases (Manji et al., 2001) and currently used antidepressants increase 
neurotransmitter availability. The present study has shown that apart from 
neurotransmission antidepressant treatment alters key cellular processes like 
energy metabolism supporting findings from previous functional genomic 
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studies (Khawaja et al., 2004; Carboni et al., 2006; McHugh et al., 2008). It is 
tempting to speculate that these altered key cellular processes are directly or 
indirectly involved in antidepressant therapeutic effects. 
 
3.1.1 Antidepressant treatment shifts energy metabolism towards 
aerobic glycolysis 
 
We identified significant alterations in energy metabolism upon paroxetine 
treatment (Webhofer et al., 2011). Most importantly, there was a fast and 
strong increase of early glycolytic intermediates in the hippocampus of DBA/2 
mice upon paroxetine treatment (Webhofer et al., 2013). Supporting the shift 
towards aerobic glycolysis upon antidepressant treatment, the antidepressant-
like 15N isotope effect in HAB mice correlated with decreases in Krebs cycle 
and oxidative phosphorylation enzyme levels (Filiou et al., 2012). In 
agreement with these results, Filiou et al. (Filiou et al., 2011b) found 
decreased Krebs cycle and oxidative phosphorylation enzyme levels in low 
anxiety LAB mice compared to anxious HAB mice. It is important to note that 
aerobic glycolysis not only provides ATP for neuronal activity but also 
influences other important cellular parameters like the redox state and 
pathways like neurogenesis (Vaishnavi et al., 2010) – a known target of 
antidepressant treatment (Santarelli et al., 2003). 
Future studies need to address the question whether directly targeting energy 
metabolism and shifting it towards aerobic glycolysis can have 
antidepressant-like effects in mouse models. In addition to assessing 
behavioral effects the emphasis of such studies should be on a critical 
evaluation of undesired side effects when directly interfering with a ubiquitous 
pathway such as energy metabolism. It may be beneficial to not directly target 
energy metabolism but related pathways that may be more relevant for 
antidepressant therapeutic effects. Future systems-based studies will 
eventually lead to an advanced understanding of neuronal and glial energy 
metabolism and its cross-talk with other pathways facilitating targeted 
therapeutic interventions. 
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3.1.2 Role of astrocytes in paroxetine treatment 
 
Combined proteomic and metabolomic analyses indicated that increased 
glycolytic intermediate levels may, at least in part, be a consequence of an 
altered glycogen metabolism (Webhofer et al., 2013). The involvement of 
glycogen metabolism points towards an important role of astrocytes, the 
primary source of glycogen in the brain (Magistretti et al., 2000), in 
antidepressant action as has been postulated before (Czeh and Di Benedetto, 
2012). It is therefore important that future studies elucidate specific roles of 
distinct cell types in antidepressant treatment. This notion is underscored by 
recent findings indicating that single cell types play distinct roles in 
antidepressant therapy (Schmidt et al., 2012) and that distinct cell types in 
different brain regions may elicit bidirectional effects on psychiatric 
phenotypes (Refojo et al., 2012). At present, however, functional genomic 
studies on single cell systems are analytically very challenging due to low 
tissue amounts and advances in analytical platforms are necessary to enable 
these studies.  
 
3.1.3 Paroxetine treatment influences amino acid metabolism 
 
Interestingly, there were opposing findings regarding proteinogenic amino 
acids that were significantly altered upon paroxetine treatment as described in 
chapters 2.1 and 2.2. Seven proteinogenic amino acids that were significantly 
increased in one study (chapter 2.1) were significantly decreased in the other 
study (chapter 2.2, alanine, leucine/isoleucine, serine, threonine, tyrosine and 
valine). GABA, a non-proteinogenic amino acid, was significantly decreased 
upon paroxetine treatment in both studies. Similar treatment paradigms but 
distinct sample preparation protocols and metabolomic platforms were 
employed in the two studies (Webhofer et al., 2011; Webhofer et al., 2013). 
Major differences between the studies included (1) duration of paroxetine 
treatment, i.e. 28 days versus 24 days, (2) metabolite extraction buffers and 
extraction protocol, i.e.  acetonitrile/isopropanol/water 3:3:2 versus 
methanol/water 4:1 and (3) metabolomics platform, i.e. GC-TOF-MS versus 
LC-SRM-MS/MS based metabolite quantitation. 
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Although the duration of chronic paroxetine treatment was similar (24 days 
versus 28 days) differences could still result from different treatment duration. 
However, both studies show increased glycolytic metabolites. The observed 
differences of proteinogenic amino acids may be due to distinct sample 
preparation strategies rather than random or systematic technical or treatment 
variability. We speculate that different sub-metabolomes may have been 
analyzed in the described studies. Future studies need to systematically 
investigate metabolic alterations in different subcellular compartments in order 
to address this question. A first line of investigation may include mitochondrial 
versus cytosol metabolite alterations upon antidepressant treatment with 
respect to the current findings related to energy metabolism. 
 
3.2 Future developments in functional genomics 
 
The present study has demonstrated the importance and benefits of 
integrated pathway analyses at both proteome and metabolome levels. 
Previous studies have also shown that there is a weak correlation between 
mRNA and protein levels (Nie et al., 2006; Gry et al., 2009) further supporting 
the need for integrated complementary -omics analyses. However, for 
successful data integration from different analytical platforms and realizing 
truly holistic answers, advances in post genomic studies have to be made. 
Post-genomic analyses are expensive and instrument-time consuming and it 
therefore takes a considerable amount of time to describe alterations at 
mRNA, protein and metabolite levels. Modern instrumentation that allows for 
reduced analysis time and increased throughput may help in this endeavor. In 
addition, instruments need to be sensitive for increased information output 
and robust in every day performance. There is also a great demand for novel 
computational tools integrating heterogeneous datasets from diverse 
analytical platforms to achieve a holistic, quantitative and predictive 
understanding of the system under investigation (Sauer and Zamboni, 2008). 
Finally, the current psychiatric pathway discovery pipeline should be 
expanded to shed light on disease etiology and mode of drug action from 
different perspectives. Important future paths may include studies on 
biological parameters such as mRNA turnover (Mitchell and Tollervey, 2001; 
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Munchel et al., 2011), protein turnover (Price et al., 2010; Zhang et al., 
2011a), protein post-translational modifications like phosphorylation 
(Christensen et al., 2010) and using diverse platforms such as single-cell 
analyses (Shi et al., 2012) or imaging studies like MALDI imaging 
(Schuerenberg et al., 2007) or multi-isotope imaging mass spectrometry 
(Steinhauser et al., 2012; Zhang et al., 2012).  
The integration of diverse technologies in combination with well characterized 
mouse models and clinical samples will lay the ground for an improved 
understanding of psychiatric diseases and treatment pathways and eventually 
lead to better diagnosis and improved treatment strategies. 
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